Study of geriatric checkups for new AML treatment plans
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at whether geriatric (age-related health) evaluations help doctors choose better treatment for newly diagnosed AML (a type of leukemia). It may help translate older adults’ needs into a clearer, safer treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new AML diagnosis confirmed by blood or bone marrow tests
- Your AML is newly diagnosed and you are considering starting a new treatment plan
- You are age 50 or older
- You can do most daily activities (activity level score 0 to 2)
- You can understand the study and sign written consent
- You can complete questionnaires by yourself or with help from someone
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are receiving strong chemotherapy. It aims to learn more about their health outcomes and better understand the disease in this age group.
This study checks “frailty” (how strong and able you are to function) to help choose better treatment for people age 60+ with certain blood cancers like acute leukemia or MDS. It may help clinicians tailor care before major treatments like transplant or CAR T-cell therapy.
This study uses a geriatric assessment to choose the best treatment for people aged 60 and older with acute myeloid leukemia (AML). The goal is to tailor therapy based on your overall health and function.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
This trial tests a special preparation (conditioning) regimen for patients 55 or older with acute myeloid leukemia (AML) who are in first remission and receiving a half-matched (haploidentical) stem cell transplant. It aims to make the transplant safer and more effective for this age group.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.